| Population 2014 |
<1 million |
| | |
| | | | | | | |
| Estimates of TB burden * 2014 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
<0.01 |
(<0.01–<0.01) |
0.58 |
(0.56–0.6) |
| Mortality (HIV+TB only) |
0 |
(–) |
0 |
(–) |
| Prevalence (includes HIV+TB) |
0.18 |
(0.084–0.31) |
29 |
(13–50) |
| Incidence (includes HIV+TB) |
0.13 |
(0.11–0.15) |
21 |
(18–24) |
| Incidence (HIV+TB only) |
<0.01 |
(<0.01–<0.01) |
0.03 |
(0.02–0.04) |
| |
|
|
|
|
| Case detection, all forms (%) |
87 |
(77–99) |
|
|
| | |
| | | | | | | |
| Estimates of MDR-TB burden * 2014 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
0 |
(0–5.7) |
40 |
(5.3–85) |
MDR-TB cases among notified pulmonary
TB cases |
0 |
(0–5) |
4 |
(0–8) |
| | |
| | | | | | | |
| TB case notifications 2014 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
63 |
|
7 |
| Pulmonary, clinically diagnosed |
27 |
|
2 |
| Extrapulmonary |
13 |
|
1 |
| |
|
|
|
| Total new and relapse |
113 |
|
|
| Previously treated, excluding relapses |
0 |
|
|
| Total cases notified |
113 |
|
|
| | |
| | | | | | | |
| Among 113 new and relapse cases: | | | | | | |
| 0 (0%) cases aged under 15 years; male:female ratio: 1.4 | | | | |
| | | | | | | |
| Reported cases of RR-/MDR-TB 2014 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
63 (100%) |
5 (50%) |
68 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
2 |
| Patients started on MDR-TB treatment *** |
|
|
2 |
| | |
| | | | | | | |
| TB/HIV 2014 |
Number |
(%) |
| TB patients with known HIV status |
94 |
(83) |
| HIV-positive TB patients |
0 |
(0) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
0 |
|
| HIV-positive TB patients on antiretroviral therapy (ART) |
0 |
|
| HIV-positive people screened for TB |
|
|
| HIV-positive people provided with IPT |
|
|
| | |
| | | | | | | |
| Treatment success rate and cohort size |
(%) |
Cohort |
| New cases registered in 2013 |
(87) |
119 |
| Previously treated cases registered in 2013 |
|
1 |
| HIV-positive TB cases, all types, registered in 2013 |
(100) |
2 |
| RR-/MDR-TB cases started on second-line treatment in 2012 |
(100) |
1 |
| XDR-TB cases started on second-line treatment in 2012 |
|
0 |
| | |
| | | | | | | |
| Laboratories 2014 |
|
| Smear (per 100 000 population) |
0.2 |
| Culture (per 5 million population) |
8.0 |
| Drug susceptibility testing (per 5 million population) |
8.0 |
| Sites performing Xpert MTB/RIF |
0 |
| Is second-line drug susceptibility testing available? |
Yes, outside
country |
| | |
| | | | | | | |
| Financing TB control 2015 |
|
| National TB programme budget (US$ millions) |
|
| % Funded domestically |
|
| % Funded internationally |
|
| % Unfunded |
|
| | |
| | | | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** Includes cases with unknown previous TB treatment history | | | |
| *** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having | |
| RR-/MDR-TB | | | | | | | |
| | | | | | | |